Clinical trial
Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine
NCT00424944 · African Malaria Network Trust, Other · Unknown status
Key facts
| NCT number | NCT00424944 |
|---|---|
| Title | Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine |
| Official title | A Single Centre, Randomised Controlled Trial to Evaluate the Safety and Immunogenicity of Recombinant Lactococcus Lactis Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine Versus Rabies Vaccine in Healthy Gabonese Adult Volunteers |
| Lead sponsor | African Malaria Network Trust, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Biological |
| Interventions | GMZ2 (malaria vaccine), GMZ2 malaria vaccine, Verorab vaccine |
| Enrollment | 40 |
| Start date | Jun 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Jan 22, 2007 |
| Last update posted | Apr 3, 2008 |
| Countries | Gabon |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: